DK0731796T3 - 1,3,5-Trisubstituerede pyrozolforbindelser til behandling af inflammation - Google Patents

1,3,5-Trisubstituerede pyrozolforbindelser til behandling af inflammation

Info

Publication number
DK0731796T3
DK0731796T3 DK95902445T DK95902445T DK0731796T3 DK 0731796 T3 DK0731796 T3 DK 0731796T3 DK 95902445 T DK95902445 T DK 95902445T DK 95902445 T DK95902445 T DK 95902445T DK 0731796 T3 DK0731796 T3 DK 0731796T3
Authority
DK
Denmark
Prior art keywords
treatment
sulfamyl
acylamino
alkoxycarbonyl
halo
Prior art date
Application number
DK95902445T
Other languages
Danish (da)
English (en)
Inventor
Thomas D Penning
John J Talley
Donald J Rogier Jr
Stella S Yu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0731796T3 publication Critical patent/DK0731796T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
DK95902445T 1993-11-30 1994-11-14 1,3,5-Trisubstituerede pyrozolforbindelser til behandling af inflammation DK0731796T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,517 US5434178A (en) 1993-11-30 1993-11-30 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
PCT/US1994/012722 WO1995015318A1 (en) 1993-11-30 1994-11-14 1,3,5-trisubstituted pyrazole compounds for treatment of inflammation

Publications (1)

Publication Number Publication Date
DK0731796T3 true DK0731796T3 (da) 2000-09-04

Family

ID=22577200

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95902445T DK0731796T3 (da) 1993-11-30 1994-11-14 1,3,5-Trisubstituerede pyrozolforbindelser til behandling af inflammation

Country Status (12)

Country Link
US (1) US5434178A (de)
EP (1) EP0731796B1 (de)
JP (1) JPH09505830A (de)
AT (1) ATE195118T1 (de)
AU (1) AU1171595A (de)
CA (1) CA2177574A1 (de)
DE (1) DE69425442T2 (de)
DK (1) DK0731796T3 (de)
ES (1) ES2150545T3 (de)
GR (1) GR3034515T3 (de)
PT (1) PT731796E (de)
WO (1) WO1995015318A1 (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5908852A (en) * 1994-11-14 1999-06-01 G. D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
AU5886296A (en) 1995-06-02 1996-12-18 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclo oxygenase-2 and 5-lipoxygenase inhibitors
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
EP0833664A1 (de) 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
ES2243978T3 (es) 1996-02-13 2005-12-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4.
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
PL195955B1 (pl) 1996-04-12 2007-11-30 Searle & Co Związek, pochodna benzenosulfonamidu, sposób jegowytwarzania, kompozycja farmaceutyczna zawierająca go oraz jego zastosowanie
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
EP1479385B1 (de) * 1996-10-15 2008-07-02 G.D. Searle LLC Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
YU53899A (sh) * 1997-04-18 2002-10-18 G.D. Searle & Co. Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
WO1999058523A1 (en) * 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-DIARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
US6649645B1 (en) * 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
CN1326848C (zh) * 1998-12-25 2007-07-18 帝国脏器制药株式会社 氨基吡唑衍生物
DE19904397A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Verwendung von Pyrazol-Carbonsäureamiden
US6509361B1 (en) * 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
DE60034785D1 (en) 1999-06-16 2007-06-21 Univ Temple 1-(4-sulfamylphenyl)-3-trifluormethyl-5-aryl-2-pyrazoline als cyclooxygenase-2 inhibitoren
EP1099695A1 (de) * 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-Aryl-1H-1,2,4-triazolverbindungen als Cyclooxygenase-2 Inhibitoren und diese enthaltende pharmazeutische Zusammensetzungen
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
TR200302047T4 (tr) 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
CA2326970C (en) 1999-12-03 2004-11-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
AU783359B2 (en) 1999-12-03 2005-10-20 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
NZ513960A (en) * 1999-12-08 2004-02-27 Pharmacia Corp Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents
US20020128267A1 (en) * 2000-07-13 2002-09-12 Rebanta Bandyopadhyay Method of using COX-2 inhibitors in the treatment and prevention of ocular COX-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
DK1303265T3 (da) * 2000-07-20 2007-11-12 Lauras As Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2004522754A (ja) * 2001-02-02 2004-07-29 ファルマシア・コーポレーション 月経困難症の治療および予防のための組み合わせ治療としてシクロオキシゲナーゼ‐２阻害剤および性ステロイドを使用する方法
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2002089798A2 (en) * 2001-05-04 2002-11-14 Merck & Co., Inc. Method and compositions for treating migraines
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
ATE298749T1 (de) 2001-07-05 2005-07-15 Pfizer Prod Inc Heterocyclo-alkylsulfonyl pyrazole als entzündungshemmende/analgetische mittel
CA2390181A1 (en) * 2001-07-05 2003-01-05 Andrei Shavnya Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20030114483A1 (en) * 2001-09-18 2003-06-19 Pharmacia Corporation Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
US20030236308A1 (en) * 2001-09-18 2003-12-25 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
MXPA04002683A (es) 2001-09-19 2004-06-18 Pharmacia Corp Compuestos bencenosulfamida pirazolil sustituidos para el tratamiento de la inflamacion.
AU2002341729A1 (en) 2001-09-19 2003-04-01 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
US20040082940A1 (en) * 2002-10-22 2004-04-29 Michael Black Dermatological apparatus and method
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US7329401B2 (en) * 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
MXPA04010186A (es) * 2002-04-18 2005-02-03 Pharmacia Corp Monoterapia para el tratamiento de la enfermedad de parkinson con inhibidor (es) de la ciclooxigenasa-2 (cox 2).
MXPA04010397A (es) * 2002-04-22 2005-02-17 Pfizer Prod Inc Inhibidores selectivos de la ciclooxigenasa-2.
AU2003229016A1 (en) * 2002-05-10 2003-11-11 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
JP2005535642A (ja) 2002-06-28 2005-11-24 ニトロメッド インコーポレーティッド オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法
WO2004004833A1 (en) * 2002-07-02 2004-01-15 Pharmacia Corporation Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event
EP1398029A1 (de) * 2002-09-10 2004-03-17 LION Bioscience AG 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
KR100470075B1 (ko) * 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470076B1 (ko) * 2002-11-27 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
CA2510445A1 (en) * 2002-12-19 2004-07-08 Pharmacia Corporation Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents
AU2003300264A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents
US20070265606A1 (en) * 2003-02-14 2007-11-15 Reliant Technologies, Inc. Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
EP2266585B1 (de) 2003-05-07 2013-06-26 Osteologix A/S Wasserlösliche Strontiumsalze zur Behandlung von Knorpel- und Knochenerkrankungen
US20050065154A1 (en) * 2003-06-24 2005-03-24 Pharmacia Corporation Treatment of migraine accompanied by nausea with a combination of cyclooxygenase-2 selective inhibitors and anti-nausea agents
CA2536173A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
JP2007504136A (ja) * 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
US7067159B2 (en) * 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
WO2005070006A2 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005097096A1 (en) * 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc A phenyl acetic acid cyclooxygenase-2 inhibitor for the treatment of ocular disorders
WO2005097110A1 (en) * 2004-03-31 2005-10-20 Pharmacia & Upjohn Company Llc Monotherapy for the modulation of intraocular pressure with cyclooxygenase-2 selective inhibitors
US7622142B2 (en) * 2004-09-14 2009-11-24 New Chapter Inc. Methods for treating glioblastoma with herbal compositions
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
WO2006052899A2 (en) * 2004-11-08 2006-05-18 Nitromed, Inc. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
US20080275093A1 (en) * 2004-11-15 2008-11-06 Nitromed, Inc. Diuretic Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
CA2595579A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
US20090042819A1 (en) * 2005-02-16 2009-02-12 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
AU2006223392A1 (en) * 2005-03-09 2006-09-21 Nicox S.A. Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
WO2006127591A2 (en) * 2005-05-23 2006-11-30 Nitromed, Inc. Organic nitric oxide enhancing salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
EP1915157A4 (de) * 2005-08-02 2010-09-01 Nicox Sa Stickoxidverstärkende antimikrobielle verbindungen, zusammensetzungen und verwendungsverfahren
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
US8067414B2 (en) * 2006-03-29 2011-11-29 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US20080208179A1 (en) * 2006-10-26 2008-08-28 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
JP2010516679A (ja) * 2007-01-19 2010-05-20 マリンクロット インコーポレイテッド 診断用および治療用シクロオキシゲナーゼ−２結合リガンド
AU2008274941A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
WO2011038261A1 (en) * 2009-09-24 2011-03-31 Selexagen Therapeutics, Inc. Heterocyclic kinase inhibitors
AR088351A1 (es) * 2011-10-31 2014-05-28 Lilly Co Eli Analogos de pirazol sustituidos
WO2014152738A1 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Lxr modulators
EP3292213A1 (de) 2015-05-04 2018-03-14 Academisch Medisch Centrum Biomarker für den nachweis von aspirinunempfindlichkeit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1261124B (de) * 1961-09-22 1968-02-15 Hoechst Ag Verfahren zur Herstellung von Pyrazolen
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
JPS5012603A (de) * 1973-06-06 1975-02-08
JPS5891301A (ja) * 1981-11-24 1983-05-31 Mitsubishi Heavy Ind Ltd アキシヤルピストン型流体機械
US4862789A (en) * 1988-02-01 1989-09-05 Vickers, Incorporated Positive displacement pump or motor utilizing a self-lubricated bearing
JPH0351516A (ja) * 1989-07-18 1991-03-05 Komatsu Ltd 液圧ポンプ用ラジアル軸受装置
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
EP0731796B1 (de) 2000-08-02
ATE195118T1 (de) 2000-08-15
US5434178A (en) 1995-07-18
WO1995015318A1 (en) 1995-06-08
JPH09505830A (ja) 1997-06-10
AU1171595A (en) 1995-06-19
CA2177574A1 (en) 1995-06-08
DE69425442T2 (de) 2001-02-08
GR3034515T3 (en) 2000-12-29
PT731796E (pt) 2001-01-31
EP0731796A1 (de) 1996-09-18
DE69425442D1 (de) 2000-09-07
ES2150545T3 (es) 2000-12-01

Similar Documents

Publication Publication Date Title
DK0731796T3 (da) 1,3,5-Trisubstituerede pyrozolforbindelser til behandling af inflammation
ES2145996T3 (es) Piridinas sustituidas con 3,4-diarilo para el tratamiento de la inflamacion.
DK0731794T3 (da) 1,4,5-Triphenyl-pyrazolforbindelser til behandling af inflammation og inflammationsbeslægtede lidelser
DK0772601T3 (da) 4,5-Substituerede imidazolylforbindelser til behandling af inflammation
CA2177576A1 (en) Substituted Pyrazolyl Benzenesulfonamides for the Treatment of Inflammation
EP1223167A3 (de) Substituierte Isoxazole zur Behandung von Entzündungen
DK0772597T3 (da) 3,4-Substituerede pyrazoler til behandling af inflammation
DK0809636T3 (da) Substituerede isoxazoler til behandling af inflammation
NO974844L (no) Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser
RU2001115829A (ru) Дикетон в качестве промежуточного продукта при получении 3-галоген-1н-пиразолов
DK0808304T3 (da) 2,3-substituerede pyridiner til behandling af inflammation
DK0794942T3 (da) Substituerede biphenylforbindelser til behandling af inflammation
DE3476199D1 (de) 5-acylamino-1-phenyl pyrazoles
WO2000018741A3 (en) Pyrazole compounds as cox-2 inhibitors
NO304314B1 (no) Cykloheksanderivater og anvendelse av forbindelsene for fremstilling av legemidler
ATE214692T1 (de) Metalloproteinase-inhibitoren
DE60321115D1 (de) Kosmetische Zusammensetzungen enthaltend ein amphoteres Tensid und ein Ceramid sowie ihre Verwedung